Peringkat dalam Saham
#25179
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Harga Saham
$1.95
Terakhir disinkronkan: 2022-07-29
Kapitalisasi Pasar
$52.48M
Perubahan (1 tahun)
0.00%
Perdagangan Cortexyme, Inc. (CRTX)
Harga CRTX dengan kapitalisasi pasar B
Kapitalisasi pasar dari Cortexyme, Inc.(CRTX)
Kapitalisasi Pasar: $52.48M
Per August 2026, Cortexyme, Inc. memiliki kapitalisasi pasar sebesar $52.48M. Ini menjadikan Cortexyme, Inc. sebagai perusahaan 25179th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Cortexyme, Inc. dari 2019 hingga 2026
CRTX dibandingkan dengan 5 teratas stocks paling populer
| Harga CRTX |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.257T
|
+10,017,403.34%
|
|
|
|
|
$4.599T
|
+8,763,132.61%
|
|
|
|
|
$4.107T
|
+7,825,441.76%
|
|
|
|
|
$3.577T
|
+6,816,746.16%
|
|
|
|
|
$2.807T
|
+5,349,526.26%
|
